Latest News
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
TÜBINGEN, GERMAN and BOSTON, MA / ACCESSWIRE / November 1, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
Why CureVac Stock Plunged Today
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 17, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 1, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Update to the Management Team
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
TÜBINGEN, GERMANY / ACCESSWIRE / July 13, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that it...
Why Shares of CureVac Jumped This Week
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
Why CureVac Stock Leaped 12% Higher Today
The war on cancer advances with the German company's latest clinical development.
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, USA / ACCESSWIRE / June 19, 2023 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / May 30, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
TÜBINGEN, GERMANY / ACCESSWIRE / May 19, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that its...
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / May 8, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 25, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial...
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 28, 2023 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"),...
CureVac Announces Proposed Public Offering of Common Shares
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 7, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced...
CureVac Welcomes Myriam Mendila as New Chief Development Officer
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 1, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that...
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 31, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its...
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 30, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced...